Cargando…
Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among K...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037584/ https://www.ncbi.nlm.nih.gov/pubmed/33808075 http://dx.doi.org/10.3390/jcm10071381 |
_version_ | 1783677177957449728 |
---|---|
author | Yu, Hun-Ju Chuang, Meng-Ni Chu, Chiao-Lun Wu, Pei-Lin Ho, Shu-Chen Kuo, Ho-Chang |
author_facet | Yu, Hun-Ju Chuang, Meng-Ni Chu, Chiao-Lun Wu, Pei-Lin Ho, Shu-Chen Kuo, Ho-Chang |
author_sort | Yu, Hun-Ju |
collection | PubMed |
description | Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among KD patients. Therefore, the aim of this study was to assess the difference in myopic incidence between Kawasaki disease (KD) patients treated with aspirin and intravenous immunoglobulin (IVIG). Materials and methods: We carried out a nationwide retrospective cohort study by analyzing the data of KD patients (ICD-9-CM code 4461) from Taiwan’s National Health Insurance Research Database (NHIRD) during the period of 1996–2013. Results: A total of 14,102 diagnosed KD were found in Taiwan during the study period. After excluded missing data, treatment strategy and age distribution, a total of 1446 KD patients were enrolled for analysis including 53 of which received aspirin (without IVIG) and 1393 of which were treated with IVIG. Patients who had myopia, astigmatism, glaucoma, cataract, etc. prior to their KD diagnosis were excluded. The age range was 0 to 6 years old. According to the cumulative curves, our results demonstrated that the myopic incidence in the IVIG group was significantly lower than the aspirin group (hazard ratio: 0.59, 95% confidence intervals: 0.36~0.96, p = 0.02). Treatment with IVIG for KD patients may have benefit for myopia control. Conclusion: Compared to aspirin, IVIG may decrease the myopic risk in KD patients. However, it needs further investigation including clinical vision survey of myopia due to the limitations of this population-based study. |
format | Online Article Text |
id | pubmed-8037584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80375842021-04-12 Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia Yu, Hun-Ju Chuang, Meng-Ni Chu, Chiao-Lun Wu, Pei-Lin Ho, Shu-Chen Kuo, Ho-Chang J Clin Med Article Kawasaki disease (KD) is a systemic vasculitis that primarily affects children under the age of 5 years old. The most significant complication is coronary artery lesions, but several ocular manifestations have also been reported. Recently, one study revealed an increasing incidence of myopia among KD patients. Therefore, the aim of this study was to assess the difference in myopic incidence between Kawasaki disease (KD) patients treated with aspirin and intravenous immunoglobulin (IVIG). Materials and methods: We carried out a nationwide retrospective cohort study by analyzing the data of KD patients (ICD-9-CM code 4461) from Taiwan’s National Health Insurance Research Database (NHIRD) during the period of 1996–2013. Results: A total of 14,102 diagnosed KD were found in Taiwan during the study period. After excluded missing data, treatment strategy and age distribution, a total of 1446 KD patients were enrolled for analysis including 53 of which received aspirin (without IVIG) and 1393 of which were treated with IVIG. Patients who had myopia, astigmatism, glaucoma, cataract, etc. prior to their KD diagnosis were excluded. The age range was 0 to 6 years old. According to the cumulative curves, our results demonstrated that the myopic incidence in the IVIG group was significantly lower than the aspirin group (hazard ratio: 0.59, 95% confidence intervals: 0.36~0.96, p = 0.02). Treatment with IVIG for KD patients may have benefit for myopia control. Conclusion: Compared to aspirin, IVIG may decrease the myopic risk in KD patients. However, it needs further investigation including clinical vision survey of myopia due to the limitations of this population-based study. MDPI 2021-03-30 /pmc/articles/PMC8037584/ /pubmed/33808075 http://dx.doi.org/10.3390/jcm10071381 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Yu, Hun-Ju Chuang, Meng-Ni Chu, Chiao-Lun Wu, Pei-Lin Ho, Shu-Chen Kuo, Ho-Chang Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title | Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title_full | Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title_fullStr | Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title_full_unstemmed | Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title_short | Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia |
title_sort | intravenous immunoglobulin treatment in kawasaki disease decreases the incidence of myopia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037584/ https://www.ncbi.nlm.nih.gov/pubmed/33808075 http://dx.doi.org/10.3390/jcm10071381 |
work_keys_str_mv | AT yuhunju intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia AT chuangmengni intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia AT chuchiaolun intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia AT wupeilin intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia AT hoshuchen intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia AT kuohochang intravenousimmunoglobulintreatmentinkawasakidiseasedecreasestheincidenceofmyopia |